Southern medical journal
-
Southern medical journal · Feb 2015
ReviewSodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Type 2 diabetes mellitus continues to be a challenging disease to manage successfully. Beyond the first-line option metformin, there are a number of classes of medications from which to select. This article reviews the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin, including their benefits, adverse effects, and potential place in therapy. ⋯ These medications also have been shown to reduce A1c when used with insulin. Some adverse effects were noted when using canagliflozin and dapagliflozin, with the most frequent being urinary tract infections and genital mycotic infections. We review the sodium-glucose cotransporter 2 inhibitors approved by the US Food and Drug Administration and their potential roles in the management of type 2 diabetes mellitus.
-
Southern medical journal · Feb 2015
ReviewUse of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors such as canagliflozin and dapagliflozin have been approved for the treatment of type 2 diabetes mellitus. A PubMed search was conducted of the literature from April 1996 to August 2014 to identify all human studies related to SGLT2 inhibitors. ⋯ SGLT2 inhibitors may be used as an add-on therapy in select and relatively healthy older patients with type 2 diabetes mellitus who are overweight and have uncontrolled hypertension. These medications should be avoided in patients who are frail, who have chronic kidney disease, and in conjunction with insulin or sulfonylureas.